<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03814759</url>
  </required_header>
  <id_info>
    <org_study_id>4-2015-0603</org_study_id>
    <nct_id>NCT03814759</nct_id>
  </id_info>
  <brief_title>Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma</brief_title>
  <official_title>Preoperative S-1 Plus Cisplatin-based Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma : Randomized, Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric cancer is a high incidence in Asia, and one of the leading cause of death in Korea. A&#xD;
      cure rate is improving due to early diagnosis. However, the 5-year survival rate of gastric&#xD;
      cancer excluding early gastric cancer is about 40 ~ 67%. Therefore, several methods for&#xD;
      lowering the recurrence rate have been attempted and concurrent chemoradiotherapy can be&#xD;
      considered as a method to lower the recurrence rate of gastric cancer. The purpose of this&#xD;
      study is to evaluate the pathologic response rate and safety of patients who underwent&#xD;
      surgery after chemoradiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2016</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological response rate</measure>
    <time_frame>10 week</time_frame>
    <description>to evaluate pathological response rate in locally advanced resectable gastric cancer</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>SP+CCRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1 20mg/m2, bid (D1~14, D22~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5) radiation 45Gy per 5 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TS-1 + cisplatin</intervention_name>
    <description>S-1 20mg/m2, bid (D1~14, D22~35) Cisplatin 30mg/m2/day (W1, 2, 4, 5)</description>
    <arm_group_label>SP+CCRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation</intervention_name>
    <description>radiation 45Gy per 5 weeks</description>
    <arm_group_label>SP+CCRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 20 years old&#xD;
&#xD;
          2. Histologically confirmed gastric adenocarcinoma&#xD;
&#xD;
          3. clinical stage : resectable gastric cancer&#xD;
&#xD;
               -  advanced confirmed (EGD)&#xD;
&#xD;
               -  extramural infiltration&gt; 1 mm (CT)&#xD;
&#xD;
               -  positive serosa invasion (EUS)&#xD;
&#xD;
          4. Eastern Cooperative Oncology Group performance status 0 or 1&#xD;
&#xD;
          5. no prior chemotherapy and radiotherapy&#xD;
&#xD;
          6. measurable lesion or evaluable lesion according to Response Evaluation Criteria in&#xD;
             Solid Tumors version 1.1 criteria&#xD;
&#xD;
          7. Patients with adequate organ function&#xD;
&#xD;
          8. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Metastasis esophageal invasion &gt; 3cm&#xD;
&#xD;
          2. inoperable peritoneal seeding disease determined by exploratory laparotomy&#xD;
&#xD;
          3. T4b invading the surrounding organs&#xD;
&#xD;
          4. lymph node metastasis outside the celiac trunk Lymph node and splenic lymph node&#xD;
&#xD;
          5. uncontrolled viral infections (HIV, HBV, HCV)&#xD;
&#xD;
          6. Pregnant or lactating women, women of childbearing potential not employing adequate&#xD;
             contraception&#xD;
&#xD;
          7. severe hypersensitivity reactions to S-1, cisplatin&#xD;
&#xD;
          8. Subjects with uncontrolled clinically significant cardiovascular medical history,&#xD;
             uncontrolled infection or complication&#xD;
&#xD;
          9. Other co-existing malignancies or malignancies diagnosed within the last 5 years&#xD;
             except for curatively treated non-melanoma skin cancer or in situ carcinoma of the&#xD;
             cervix&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hyo Song Kim</last_name>
    <phone>82-2-2228-8124</phone>
    <email>hyosong77@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyo Song Kim</last_name>
      <phone>82-2-2228-8124</phone>
      <email>hyosong77@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 23, 2019</study_first_submitted>
  <study_first_submitted_qc>January 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2019</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Hyo Song Kim</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

